Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-10-08 16:45 |
Cantargia slutför rekryteringen och rapporterar en positiv interims-uppdatering…
|
Swedish | 246.3 KB | ||
| 2020-10-08 16:45 |
Cantargia completes recruitment and reports positive interim update in CAN04 pa…
|
English | 246.1 KB | ||
| 2020-10-02 17:10 |
Cantargia reports first patient treated with CAN04 in a US phase I study invest…
|
English | 180.7 KB | ||
| 2020-10-02 17:10 |
Cantargia rapporterar att första patienten behandlats med CAN04 i en fas I stud…
|
Swedish | 185.5 KB | ||
| 2020-10-01 15:17 | English | 33.9 KB | |||
| 2020-10-01 10:30 |
Sunstone säljer 1 500 000 Cantargia-aktier till en av Cantargias större institu…
|
Swedish | 175.2 KB | ||
| 2020-09-23 12:15 |
Cantargia reports high response rates with CAN04 combination therapy in NSCLC a…
|
English | 217.5 KB | ||
| 2020-09-23 12:15 |
Cantargia rapporterar höga responsnivåer med CAN04 kombinationsterapi i NSCLC o…
|
Swedish | 219.7 KB | ||
| 2020-09-21 14:30 |
Notice of extraordinary general meeting in Cantargia AB (publ)
|
English | 190.3 KB | ||
| 2020-09-21 14:30 |
Kallelse till extra bolagsstämma i Cantargia AB (publ)
|
Swedish | 178.3 KB | ||
| 2020-08-24 14:24 | English | 7.5 MB | |||
| 2020-08-20 08:30 | Swedish | 484.7 KB | |||
| 2020-08-20 08:30 | English | 517.2 KB | |||
| 2020-07-31 08:30 |
New number of shares and votes in Cantargia
|
English | 164.3 KB | ||
| 2020-07-31 08:30 |
Nytt antal aktier och röster i Cantargia
|
Swedish | 161.9 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
